

JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Hyderabad-500008.
CONSOLIDATED UN AUDITED FINANCIAL RESULTS FOR THE QUARTER AND 9 MONTHS ENDED 31ST DEC, 2021
Rupees in Lakhs

Sl.No	Particulars	Quarter Ended			9 Months Ended		Year Ended
		31-12-2021 Un Audited	30-09-2021 Un Audited	31-12-2020 Un Audited	31-12-2021 Un Audited	31-12-2020 Un Audited	
1	Income						
	(a) Revenue From Operations	2101.77	1864.81	1578.73	5586.96	3250.31	4787.59
	(b) Other Income	38.87	33.43	23.34	80.79	84.78	93.91
	(c) Unbilled Revenue	0.00	0.00	0.00	0.00	53.00	53.00
	Total income	2,140.64	1,898.24	1,602.07	5,667.75	3,388.09	4,934.50
2	Expenses						
	(a) Cost of Material Consumed	90.73	143.41	87.49	317.83	157.4	274.55
	(b) Purchase of stock-in-trade	-	-	-	-	-	-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	129.58	129.84	-89.00	244.62	-176.60	-210.30
	(d) Employee benefit expense	507.12	459.28	328.24	1408.23	893.01	1253.34
	(e) Finance Cost	22.17	27.74	58.59	76.80	194.15	209.36
	(f) Depreciation and Amortisation expense	98.38	99.5	99.62	297.44	298.19	396.83
	(g) Other Expenses	700.83	506.52	422.17	1728.94	1040.01	1645.78
	Total Expenses	1,548.81	1,366.29	907.11	4,073.86	2,406.16	3,569.56
3	Profit before exceptional items and Tax	591.83	531.95	694.96	1,593.89	981.93	1,364.94
4	Add(+)/Less(-) Exceptional items	-	-	-	-	-	0.00
5	Profit/ (Loss) before Tax	591.83	531.95	694.96	1,593.89	981.93	1,364.94
6	Tax Expenses	164.77	158.16	121.97	461.06	192.17	190.94
7	Profit(Loss) for the Period from Continuing Operations	427.06	373.79	572.99	1132.83	789.76	1174.00
8	Profit(Loss) from Discontinuing Operations	-	-	-	-	-	-
9	Tax Expenses on discontinuing Operations	-	-	-	-	-	-





Sl.No	Particulars	Quarter Ended			9 Months Ended		Year Ended
		31-12-2021 Un Audited	30-09-2021 Un Audited	31-12-2020 Un Audited	31-12-2021 Un Audited	31-12-2020 Un Audited	
10	Profit(Loss) from Discontinuing Operations after Tax		-	-			-
11	Profit(Loss) for the period	427.06	373.79	572.99	1,132.83	789.76	1,174.00
12	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	1.11	0.62	-0.28	2.37	-0.83	5.96
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period	428.17	374.41	572.71	1,135.20	788.93	1,179.96
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15
15	Other equity excluding revaluation reserve						1972.12
16	Earnings per Equity share (for continuing operations)						
	a) Basic (Amount in Rupees)	2.80	2.45	3.74	7.42	5.16	7.71
	b) Diluted (Amount in Rupees)	2.80	2.45	3.74	7.42	5.16	7.71
17	Earnings per Equity share (for discontinued operations)						
	a) Basic (Amount in Rupees)						
	b) Diluted (Amount in Rupees)						
18	Earnings per Equity share (for Continuing & discontinued operations)						
	a) Basic (Amount in Rupees)	2.80	2.45	3.74	7.42	5.16	7.71
	b) Diluted (Amount in Rupees)	2.80	2.45	3.74	7.42	5.16	7.71

Notes to the Consolidated Un Audited Financial Results

- 1 The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- 2 The above results have been reviewed by the Audit Committee at its meeting held on 14.02.2022 and approved by the Board of Directors of the Company on the same date. These Results are also subjected to Limited Review by the Company's Statutory Auditors.
- 3 The Group currently has two segments (i) clinical research services and (ii) Information technology services.
- 4 The company has considered the possible effects that may result from the pandemic relating to Covid 19 on the carrying amounts of receivables, inventories, property, plant and equipment and intangible assets. In developing the assumptions relating to the future possible uncertainties in the global economic conditions, the Company has, at the date of approval of these standalone financial results, used internal and external sources of information, including economic forecasts and estimates from market sources, on the expected future performance of the company. On the basis of evaluation and current indicators of future economic conditions, the Company expects to recover the carrying amounts of the above assets and does not anticipate any impairment to these financial and non-financial assets. However, the impact assessment of Covid-19 is a continuing process, given
- 5 Figures for the previous periods have been rearranged wherever necessary.
- 6 The above consolidated financial results include the Un Audited financial results of the wholly owned subsidiaries, M/s Enhops Solutions Pvt Ltd & Enhops Inc.

(Signature)



(Signature)

SEGMENT-WISE REVENUE, RESULTS & CAPITAL EMPLOYED (Consolidated Unaudited)
UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE 9 MONTHS ENDED 31ST DEC, 2021

Particulars	Quarter Ended			9 Months Ended		Year Ended Audited
	31-12-2021 Un Audited	30-09-2021 Un Audited	31-12-2020 Un Audited	31-12-2021 Un Audited	31-12-2020 Un Audited	
SEGMENT REVENUE: (Net Sales / Income from Operations)						
a) Clinical Research Services	1,645.28	1,640.50	1,465.64	4,669.75	2,921.04	4,284.79
b) Information Technology Services	495.36	257.74	136.43	998.00	467.05	649.71
Total:	2,140.64	1,898.24	1,602.07	5,667.75	3,388.09	4,934.50
LESS: Inter Segment revenue						
Net Sales/ income from Operations.	2,140.64	1,898.24	1,602.07	5,667.75	3,388.09	4,934.50
SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST :						
a) Clinical Research Services	567.72	528.83	763.28	1,548.55	1,110.11	1,489.47
b) Information Technology Services	46.27	30.86	(9.73)	122.14	65.97	84.83
Total:	613.99	559.69	753.55	1,670.69	1,176.08	1,574.30
LESS:						
i) Interest	22.17	27.74	58.59	76.80	194.15	209.36
ii) Other Un-Allocable Expenditure	-	-	-	-	-	-
iii) Un-Allocable Income	-	-	-	-	-	-
TOTAL PROFIT /(-LOSS) BEFORE TAX	591.82	531.95	694.96	1,593.89	981.93	1,364.94

Place: Hyderabad
Date: 14.02.2022

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors

M. Srikanth Sasidhar
M. Srikanth Sasidhar
Vice Chairman & Managing Director

